ArticleJournal of obesity & metabolic syndrome2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Low Handgrip Strength Are Associated with a Higher Risk of Cardiovascular Disease.
Article in Journal of obesity & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to investigate the influence of metabolic dysfunction-associated steatotic liver disease (MASLD) and handgrip strength (HGS) on the risk of atherosclerotic cardiovascular disease (ASCVD) in the general population. Methods: We used data from 20,611 individuals from the 2014-2019 Korea National Health and Nutrition Examination Survey. MASLD was defined as a Framingham steatosis index of ≥23. Low HGS was defined as <28 kg in men and <18 kg in women. The 10-year ASCVD risk score was assessed, and high-probability ASCVD was defined as >10%. Results: Individuals with both MASLD and low HGS had a greater risk of high-probability ASCVD (odds ratio [OR], 6.88; 95% confidence interval [CI], 6.81 to 6.97; Conclusion: Individuals with MASLD and low HGS had a significantly higher risk of ASCVD than those without MASLD. Concurrent advanced liver fibrosis was further associated with increased ASCVD risk among individuals with MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.